Cyclin Dependent Kinase (CDK)4/6 Inhibitor, PD0332991 in Advanced Non-small Cell Lung Cancer NSCLC.

Exclusion Criteria

• •Inability to understand or sign the informed consent document
• •Inability or unwillingness to take oral medications
• •No available tissue specimen for p16 analysis
• •Chemotherapy or radiotherapy within 3 weeks prior to beginning the study drug
• •Other investigational agents within 4 weeks prior to beginning the study drug
• •All side effects from previous chemotherapy, radiotherapy or investigational agents not resolved, returned to baseline or returned to Grade 1 toxicity (exceptions are grade 2 alopecia and grade 2 peripheral neuropathy)
• •Major surgery within 4 weeks prior to beginning the study drug
• •Surgical scar from previous surgery not healed prior to beginning the study drug
• •High-dose or chronic steroid use
• •High-dose statins within 7 days
• •History of rhabdomyolysis
• •Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, uncontrolled diabetes, stroke or myocardial infarction within 3 months, or psychiatric illness/social situations that would limit compliance with study requirements.
• •Baseline corrected QT interval (QTc) \>470ms
• •Pre-existing clinically significant cardiac, hepatic or renal dysfunction at the discretion of the treating physician
• •Untreated or uncontrolled (symptomatic or asymptomatic) brain metastases
• •Leptomeningeal carcinomatosis
• •Inability or unwillingness to use contraception during the treatment period by patients with reproductive potential.
• •Pregnant or breastfeeding women
• •HIV-positive patients on combination antiretroviral therapy